Bevacizumab: Direct anti-VEGF therapy in renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 10, 2008, Pages 1545-1557

  Escudier, Bernard ^a   Cosaert, Jan ^b   Pisa, Pavel ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Antiangiogenic drug; Bevacizumab; Efficacy; IFN ; Low dose IFN; Renal cell carcinoma; Tolerability

Indexed keywords

ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CYTOKINE; ERLOTINIB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2A INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VON HIPPEL LINDAU PROTEIN;

ADJUVANT THERAPY; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; DEPRESSION; DIALYSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPISTAXIS; EUROPEAN UNION; FATIGUE; GENE MUTATION; GOLD STANDARD; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTENSION; KIDNEY CARCINOMA; LOW DRUG DOSE; MALAISE; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEPHRECTOMY; NONHUMAN; OBESITY; PRACTICE GUIDELINE; PREDICTION; PROTEINURIA; RESPIRATORY FAILURE; RISK FACTOR; SMOKING; STOMATITIS; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MUTATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 55249100794     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.10.1545     Document Type: Article

References (83)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18, 581-592 (2007).
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335, 865-875 (1996).
4. Corgna E, Betti M, Gatta G, Roila F, De Mulder PH. Renal cancer. Crit. Rev. Oncol. Hematol. 64, 247-262 (2007).
5. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J. Urol. 176, 2353-2358 (2006).
6. Levi F, Ferlay J, Galeone C et al. The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int. 101, 949-958 (2008).
7. Bosetti C, Bertuccio P, Levi F et al. Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis, Ann. Oncol. 19, 631-640 (2008).
8. Karim-Kos HE, de Vries E, Soerjomataram I et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur. J Cancer 44(10), 1345-1389 (2008).
9. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am. J. Surg. Pathol. 27, 612-624 (2003).
10. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J. Urol. 170, 2163-2172 (2003).
11. Vira MA, Novakovic KR, Pinto PA, Linehan WM. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies. BJU Int. 99, 1223-1229 (2007).
12. Bolton DM, Wong P, Lawrentschuk N. Renal cell carcinoma: imaging and therapy. Curr. Opin. Urol. 17, 337-340 (2007).
13. Ljungberg B, Hanbury DC, Kuczyk MA et al. Renal cell carcinoma guideline. Eur. Urol. 51, 1502-1510 (2007).
14. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
15. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncot. 20, 289-296 (2002).
16. Porta C, Paglino C, Imarisio I, Bonomi L. Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents. Scientific World Journal 7, 837-849 (2007).
17. Coppin C, Porzsolt F, Awa A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. CD001425 (2005).
18. Yang JC, Childs R. Immunotherapy for renal cell cancer. J. Clin. Oncol. 24, 5576-5583 (2006).
19. Fossa SD. Interferon in metastatic renal cell carcinoma. Semin. Oncol. 27, 187-193 (2000).
20. Pyrhonen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon a-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol. 17, 2859-2867 (1999).
21. Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results ofa randomised controlled trial. Lancet 353, 14-17 (1999).
22. Negrier S, Perol D, Ravaud A et al. Medroxyprogesterone, interferon α-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110, 2468-2477 (2007).
23. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncolegist 6, 34-55 (2001).
24. Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 24, 5584-5592 (2006).
25. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. BJU Int. 99, 1282-1288 (2007).
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309 (1989).
27. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004).
28. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003).
29. Ferrara N, Chen H, Davis-Smyth T et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med. 4, 336-340 (1998).
30. Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439 (1996).
31. Gerber HP, Vu TH, Ryan AM et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5, 623-628 (1999).
32. Bloch W, Huggel K, Sasaki T et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 14, 2373-2376 (2000).
33. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl. 3), 4-10 (2005).
34. Kaelin WG Jr. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem. Biophys. Res. Commun. 338, 627-638 (2005).
35. Folkman, J. Antiangiogenesis agents. In: Cancer Principles and Practice of Oncology. 7th Edition. DeVita VT, Helmann S, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 2865-2882 (2005).
36. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13, 680s-684s (2007).
37. Herbst C, Kosmehl H, Stiller KJ et al. Evaluation of microvessel density by computerised image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis. J. Cancer Res. Clin. Oncol. 124, 141-147 (1998).
38. Jacobsen J, Grankvist K, Rasmuson T et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 93, 297-302 (2004).
39. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 349, 419-421 (2003).
40. Iliopoulos O. Molecular biology of renal cell cancer and the identification of therapeutic targets. J. Clin. Oncol. 24, 5593-5600 (2006).
41. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7, 53-64 (1992).
42. Kim KJ, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
43. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95, 1789-1797 (1995).
44. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593-4599 (1997).
45. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147 (2004).
46. Mancuso MR, Davis R, Norberg SM et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006).
47. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin. Oncol. 29, 3-9 (2002).
48. Tong RT, Boucher Y, Kozin SV et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 64, 3731-3736 (2004).
49. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer 88, 1979-1986 (2003).
50. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006).
51. Escudier BJ, Ravaud A, Bracarda S et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-α2a (IFN) in subgroups of patients (pts) with metastatic renal cell carcinoma (mRCC). Presented at: Genitourinary Cancers Symposium 14-16 February, 2008 (Abstract 358).
52. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333, 328-335 (2005).
53. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427-434 (2003).
54. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res. 10, 6367S-6370S (2004).
55. Viloria-Petit A, Crombet T, Jothy S et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 61, 5090-5101 (2001).
56. Bukowski RM, Kabbinavar FF, Figlin RA et al. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J. Clin. Oncol. 25, 4536-4541 (2007).
57. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007).
58. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
59. Miller K, Wang M, Gralow j et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
60. Ferrantini M, Capone I, Belardelli F. Interferon-α and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 89, 884-893 (2007).
61. Bracarda S, Koralewski R, Pluzanska A et al. Bevacizumab/ interferon-α2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN). Eur. J. Cancer Suppl. 5(4), 281-282 (2007) (Abstract 4008).
62. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Ann. Oncol. 19(8), 1470-1476 (2008).
63. Rini B, Halabi S, Rosenberg J et al. CALGB 90206: a Phase III trial of bevacizumab plus interferon-α monotherapy in metastatic renal cell carcinoma. Presented at: Genitourinary Cancers Symposium. 14-16 February, 2008 (Abstract 350).
64. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5, 2726-2734 (1999).
65. von Marschall Z, Scholz A, Cramer T et al. Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl Cancer Inst. 95, 437-448 (2003).
66. Dinney CP, Bielenberg DR, Perrotte P et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α administration. Cancer Res. 58, 808-814 (1998).
67. Melichar B, Kowalski J, Pluzanska A et al. First-line bevacizumab improves progression-free survival with reduced doses of interferon-α2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN). Eur. J. Cancer Suppl. 5, 304 (2007).
68. Ryan CW, Goldman BH, Lara PN Jr et al. Sorafenib with interferon α-2b as first-line treatment of advanced renal carcinoma: a Phase II study of the Southwest Oncology Group. J. Clin. Oncol. 25, 3296-3301 (2007).
69. Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon β-2b as first- or second-line therapy in patients with metastatic renal cell-cancer. J. Clin. Oncol. 25, 3288-3295 (2007).
70. Bracarda S, Porta C, Boni C et al. Randomized prospective Phase II trial of two schedules of sorafenib daily and interferon-a2a (IFN) in metastatic renal cell carcinoma (MRCC) (RAPSODY): GOIRC Study 0681. Presented at: 2008 Genitourinary Cancers Symposium. 14-16 February, 2008 (Abstract 357).
71. Sosman JA, Puzanov I, Atkins MB. Opportunities and obstacles to combination targeted therapy in renal cell cancer. Clin. Cancer Res. 13, 764S-769S (2007).
72. Feldman DR, Kondagunta GV, Ronnen EA et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 25, 259S (2007) (Abstract 5099).
73. Merchan JR, Liu G, Fitch T et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J. Clin. Oncol. 25, 243S (2007) (Abstract 5034).
74. Whorf RC, Hainsworth J, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J. Clin. Oncol. 26(Suppl.), 252S(2008) (Abstract 5010).
75. Kondagunta GV, Hodes G, Figlin R et al. Sunitinib malate (SU) plus interferon (IFN) in first line metastatic renal cell cancer (mRCC): results of a dose-finding study. J. Clin. Oncol. 25 (Suppl.), 260S (2007) (Abstract 5101).
76. Sosman JA, Flaherty K, Atkins MB et al. A Phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (pts). J. Clin. Oncol. 24, 128S (2006).
77. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized Phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25, 260S (2007) (Abstract 5104).
78. Hutson TE, George DJ, Michaelson MD et al. A Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. Eur. J. Cancer Suppl. 5, 301-301 (2007).
79. Drabkin HA, Figlin R, Stadler WM et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J. Clin. Oncol. 25, 245S (2007) (Abstract 5041).
80. Hutson TE, Davis ID, Machiels JH et al. Biomarkcr analysis and final efficary and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J. Clin. Oncol. 26, 261S (2008) (Abstract 5046).
81. Dutcher J, Wilding G, Hudes GR et al. Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone. J. Clin. Oncol. 26, 281S (2008) (Abstract 5127).
82. Jac J, Amato RJ, Giessinger S, Saxena S, Willis JP. A Phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) inpatients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J. Clin. Oncol. 26, 277S (2008) (Abstract 5113).
83. Motzer RJ, Escudier BJ, Oudard A et al. RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter Phase-III study. J. Clin. Oncol. 26, 1009S (2008) (Abstract LBA5026).